By Fineline Cube 
US-based Eli Lilly & Co. (NYSE: LLY) entered into a collaboration and licensing agreement with Sweden’s Camurus (STO: CAMX). The deal grants Lilly an exclusive global license to develop, manufacture, and commercialize long-acting incretin products for cardiovascular and metabolic health using Camurus’ FluidCrystal technology.
Deal Scope
The agreement covers up to four of Lilly’s patented drug compounds, including dual-target GIP/GLP-1 receptor agonists and triple-target GIP/GCG/GLP-1 receptor agonists. Lilly also has the option to include amylin receptor agonists.
Financial Terms
Camurus is eligible to receive up to USD 290 million in upfront, development, and regulatory milestone payments. Additionally, the company can receive up to USD 580 million in sales-based milestone payments. Camurus will also earn tiered mid-single-digit percentage royalties on global net product sales.-Fineline Info & Tech